JP2000344681A5 - - Google Patents

Download PDF

Info

Publication number
JP2000344681A5
JP2000344681A5 JP1999152578A JP15257899A JP2000344681A5 JP 2000344681 A5 JP2000344681 A5 JP 2000344681A5 JP 1999152578 A JP1999152578 A JP 1999152578A JP 15257899 A JP15257899 A JP 15257899A JP 2000344681 A5 JP2000344681 A5 JP 2000344681A5
Authority
JP
Japan
Prior art keywords
growth factor
hepatocyte growth
administration
drug holiday
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1999152578A
Other languages
Japanese (ja)
Other versions
JP2000344681A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP11152578A priority Critical patent/JP2000344681A/en
Priority claimed from JP11152578A external-priority patent/JP2000344681A/en
Publication of JP2000344681A publication Critical patent/JP2000344681A/en
Publication of JP2000344681A5 publication Critical patent/JP2000344681A5/ja
Pending legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項１】 肝実質細胞増殖因子を有効成分として含む医薬であって、十分な休薬期間を投与期間中に少なくとも１つ設けて間歇投与するための医薬。
【請求項２】 休薬期間が１日以上である請求項１に記載の医薬。
【請求項３】 肝実質細胞増殖因子に由来する腎毒性を軽減ないし排除するための請求項１又は２に記載の医薬。
【請求項４】 肝実質細胞増殖因子を有効成分として含む医薬の投与計画であって、十分な休薬期間を投与期間中に少なくとも１つ設けて肝実質細胞増殖因子を間歇投与する投与計画。
【請求項５】 休薬期間が１日以上である請求項４に記載の投与計画。
【請求項６】 肝実質細胞増殖因子に由来する腎毒性を軽減ないし排除するための請求項４又は５に記載の投与計画。 [Claims]
1. A medicament comprising hepatocyte growth factor as an active ingredient, which is provided for intermittent administration by providing at least one sufficient drug holiday during the administration period.
2. The medicament according to claim 1, wherein the drug holiday is one day or more.
3. The medicament according to claim 1, for reducing or eliminating nephrotoxicity derived from hepatocyte growth factor.
4. A dosing schedule for a medicament containing a hepatocyte growth factor as an active ingredient, wherein the hepatocyte growth factor is administered intermittently by providing at least one sufficient drug holiday during the administration period.
5. The administration schedule according to claim 4, wherein the drug holiday is one day or more.
6. The administration schedule according to claim 4 or 5, for reducing or eliminating nephrotoxicity derived from hepatocyte growth factor.

JP11152578A 1999-05-31 1999-05-31 Hgf-containing medicine Pending JP2000344681A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11152578A JP2000344681A (en) 1999-05-31 1999-05-31 Hgf-containing medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11152578A JP2000344681A (en) 1999-05-31 1999-05-31 Hgf-containing medicine

Publications (2)

Publication Number Publication Date
JP2000344681A JP2000344681A (en) 2000-12-12
JP2000344681A5 true JP2000344681A5 (en) 2006-07-13

Family

ID=15543540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11152578A Pending JP2000344681A (en) 1999-05-31 1999-05-31 Hgf-containing medicine

Country Status (1)

Country Link
JP (1) JP2000344681A (en)

Similar Documents

Publication Publication Date Title
JP2002511411A5 (en)
MXPA03007712A (en) Pharmaceutical salts.
DK1117383T3 (en) Dosage forms comprising therapeutic formulation
AU3218299A (en) Press coated, pulsatile drug delivery system suitable for oral administration
IS5404A (en) Pharmaceutical preparation containing chloronate as the active ingredient and silicified microcrystalline cellulose as a carrier
MX2007015480A (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption.
DE59907481D1 (en) CONTROLLING RELEASING PHARMACEUTICAL COMPOSITION WITH TILIDINE MESYLATE AS AN ACTIVE SUBSTANCE
MY125485A (en) Oral treatment of companion animals with extoparasiticidal spinosyns.
ZA200000169B (en) Process for the preparation of pellets with a content of up to 90 wt.% of a pharmaceutical active ingredient.
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
GR1003658B (en) Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
JP2000159790A5 (en)
IL150528A0 (en) Ibuprofen containing active agent preparation
ATE262893T1 (en) DOSAGE FORMS FOR THE TREATMENT OF ORAL MYCOSES
HU9301672D0 (en) Method for manufacturing solid dosing forms of medicaments with controlled releasing of active agents
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
FR2842524B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 3-GUANIDINOCARBONYL-1-HETEROARYL-PYRROLE DERIVATIVE, PROCESS FOR PREPARING THE SAME AS MEDICAMENTS
JP2000344681A5 (en)
NO975371D0 (en) Pharmaceutical composition prepared by adding a flavoring carrier to a drug
DK0469440T3 (en) Solid oral dosage forms containing as active ingredient ifosamide
JP2002501021A5 (en)
ATE234096T1 (en) PHARMACEUTICAL COMPOSITION FOR SYSTEMIC TRANSDERMAL ADMINISTRATION CONTAINING THE ACTIVE INGREDIENT MORPHINE-6-GLUCURONIDE
MY142361A (en) Sustained-release pharmaceutical composition for pulmonary administration
ZA200202426B (en) Pyrimidine derivatives, process for preparing the derivatives and drugs containing the same as the active ingredient.